{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 40,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "The slide uses a combination of big numbers and bulleted lists to frame the market opportunity and clinical unmet need.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/26",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.79
      },
      "kind": "list",
      "text": "Internal success threshold: 2L+ ORR of ~15% (approvability bar based on precedent); 15%+ (commercially relevant) following BA3011 monotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c24f4d7-7327-409c-a9fd-27a9592d01bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Target population: ~12K ROR2+ addressable 2L+ patients/year in the U.S., based on a ROR2 positivity rate of ~60%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49d59678-d257-47a2-8363-458b97fa1b90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.03,
        "y": 0.184
      },
      "kind": "metric",
      "text": ">400K people living with head and neck cancer (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "392fc958-cd7b-469c-bd37-010239b1d964",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.44
      },
      "kind": "metric",
      "text": "2L+ limited effective options post 1L",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "838e5037-6c1a-4aba-816f-04dae14564b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.184
      },
      "kind": "metric",
      "text": "~66K newly diagnosed cases / year (U.S.)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce24f93d-11a4-477f-9d10-13c25735c7d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.03,
        "y": 0.44
      },
      "kind": "metric",
      "text": "~50% with locally advanced disease develop recurrent or refractory disease",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa86f6bb-223d-4512-8545-ef20db63bfea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.7,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Available Treatment: 1L: Pembro, cetuximab, platinum 36% ORR; 2L+: ICIs 13% - 16% ORR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d709be97-5b3f-4b7b-9d63-343d4cdf3543",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.11,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Clarivate, Disease Landscape and Forecast: SCCHN (2022); Argiris A, et al.(2017); Future Oncology, Jan. 2019; Ketruda USPI; Opdivo USPI.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4be0f9-1c89-4a60-8293-5eb4baf89e76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Potential market opportunity in SCCHN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc107767-f4e6-4baf-b249-212b21eeba81",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}